menu toggle

Insights

Perspective, tips, and resources for moving health forward

abstract-brand-colors-texture-2
All Insights Health Systems Pharmacies Physician Practices Manufacturers Animal Health
AmerisourceBergen

What to consider when building a channel strategy for a rare disease product

Inverted color AmerisourceBergen icon
AmerisourceBergen
August 2022

Orphan drugs: trapped in the lock? A review of the lock system in the Netherlands

Xcenda_2_3_Card-02
HTA Quarterly
May 2022
Panama Canal Orphan Drug Lock Article Image

Manufacturers

Nine questions about rare and orphan drug commercialization

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2022
GettyImages-1251485261_sRGB_JPG

Manufacturers

On-demand webinar: Success factors for commercializing rare disease and orphan drugs

Inverted color AmerisourceBergen icon
AmerisourceBergen
April 2021
Commercializing rare and orphan disease products

Manufacturers

Mind the (Evidence) Gap

Kim McLeod
Kim McLeod, MPH
Xcenda
February 2020
MindtheGap

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part Two

Stojanovska_Ana
Ana Stojanovska
Biopharma Services
June 2018

An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.

Manufacturers

How to Navigate Cell and Gene Therapy Reimbursement: Part One

Stojanovska_Ana
Ana Stojanovska
Biopharma Services
June 2018

An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.

Manufacturers

Understanding the Rare Disease Journey

Inverted color AmerisourceBergen icon
AmerisourceBergen
February 2017

An interview with Matt George, patient advocate and survivor of paroxysmal nocturnal haemoglobinuria (PNH), a debilitating, rare and life-threatening disorder.